The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 22, 2014

Filed:

Oct. 23, 2007
Applicants:

John J. Stankus, Campbell, CA (US);

Florian N. Ludwig, Mountain View, CA (US);

Evgenia Mandrusov, Santa Clara, CA (US);

Liangxuan Zhang, Palo Alto, CA (US);

Hong MA, Cupertino, CA (US);

Jinping Wan, Sunnyvale, CA (US);

Shubhayu Basu, Mountain View, CA (US);

Inventors:

John J. Stankus, Campbell, CA (US);

Florian N. Ludwig, Mountain View, CA (US);

Evgenia Mandrusov, Santa Clara, CA (US);

Liangxuan Zhang, Palo Alto, CA (US);

Hong Ma, Cupertino, CA (US);

Jinping Wan, Sunnyvale, CA (US);

Shubhayu Basu, Mountain View, CA (US);

Assignee:

Abbott Cardiovascular Systems Inc., Santa Clara, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/127 (2006.01); A61F 2/00 (2006.01); A61K 9/14 (2006.01); C12N 5/071 (2010.01);
U.S. Cl.
CPC ...
Abstract

Disclosed are compositions with sustained-release carriers associated with at least two different types of growth factors and methods of fabrication and treatments thereof. In some embodiments, simultaneous release of the growth factors may be preferred while in other embodiments, sequential release of the growth factors may be preferred. Application of at least two growth factors to an injury site, e.g., compromised cardiac tissue caused by, for example, myocardial infarction or ischemic heart failure, may better mimic and induce the complex growth factor signaling pathways necessary to improve cardiac function. When applied to a patient after a myocardial infarction or ischemic heart failure, multiple growth factors within a sustained-release carrier platform or platforms may cause a synergistic effect on injected cells intending to alleviate left ventricle remodeling. Methods of treatment include percutaneous, sub-xiphoid, and open chest methods using catheters and/or syringes.


Find Patent Forward Citations

Loading…